Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04226690 · ClinicalTrials.gov registry record · Phase 1
Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04226690 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 24 participants.
The verdict
NCT04226690, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination with Tetrahydrocannabinol and matched Placebo (PLA).
Interventions
- DRUG Active CBD/THC Dose 1
- DRUG Active CBD/THC Dose 2
- DRUG matched placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04226690
The ClinicalTrials.gov registry entry for NCT04226690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Active CBD/THC Dose 1 is the first listed.
NCT04226690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04226690 about?
NCT04226690 is a clinical study titled "Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products". This proposal aims to systematically examine the safety and pharmacokinetic/pharmacodynamic profile and the physiologic, neuroendocrine and behavioral stress and pain responses to acute single doses and repeated dosing of oral tablet formulation of natural Cannabidiol (CBD) alone and in combination ...
What is the current status of trial NCT04226690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-11-15. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04226690?
The interventions under investigation include: Active CBD/THC Dose 1 (DRUG), Active CBD/THC Dose 2 (DRUG), matched placebo comparator (DRUG).
Who is sponsoring clinical trial NCT04226690?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.